Neuronetics launches $30 million public stock offering to refinance debt
+2 new sources since this summary was written
Neuronetics announced an underwritten public offering of 18,750,000 common shares at $1.60 each, with a 30‑day option for underwriters to buy up to an additional 2,812,500 shares. The company plans to use part of the net proceeds to repay a term loan and the remainder for general corporate purposes, while also amending its credit agreement to reduce revenue covenants if a $15 million prepayment is made by November 30, 2026. The stock fell 10% in after‑hours trading after the launch and dropped another 13% in extended trading after pricing.
Why it matters
The firm says the cash will help settle debt and mitigate the going‑concern warning noted in its recent Form 10‑Q filing; analysts note that the dilution and debt repayment could pressure the share price in the short term.
Key facts
- 1The offering comprises 18,750,000 shares priced at $1.60 per share. investing.com
- 2Underwriters received a 30‑day right to purchase up to 2,812,500 additional shares at the same price. investing.com
- 3Gross proceeds are expected to be about $30 million before underwriting discounts and other expenses. investing.com
- 4The transaction is slated to finalize near November 12, 2026, pending standard closing requirements. investing.com
- 5Amendment No. 6 to the credit facility requires a prepayment of at least $15 million by November 30, 2026 to reduce revenue covenants. investing.com
- 6Shares dropped roughly 10% in after‑hours trading after the offering was announced. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.